Location History:
- Jupiter, FL (US) (1995)
- Rockville, MD (US) (2001 - 2007)
Company Filing History:
9 out of 3,539 
2 out of 832,843 Years Active: 1995-2007
Title: Jerry M Collins: Innovator in Antitumor Therapy
Introduction
Jerry M Collins is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of antitumor therapy, holding a total of 11 patents. His work focuses on the innovative use of radio-labeled antitumor drugs, which has the potential to revolutionize cancer treatment.
Latest Patents
One of his latest patents involves the imaging of drug accumulation as a guide to antitumor therapy. This invention describes a method of administering a radio-labeled anticancer drug to a patient and utilizing Positron Emission Tomography (PET) imaging to monitor the delivery of these drugs to tumors. The method can predict the effectiveness of therapy with specific antitumor drugs or combinations thereof. It also assesses the effectiveness of modulators of cellular accumulation, individualizes therapy, and evaluates the effectiveness of antitumor drugs concerning particular cancers. Preferred drugs in this invention include labeled taxanes such as C-paclitaxel and C-docetaxel, labeled anthracyclines like C-doxorubicin and C-epirubicin, and other radio-labeled drugs such as C-topotecan and C-mitoxantrone. The invention further details methods for preparing these radio-labeled drugs.
Career Highlights
Throughout his career, Jerry M Collins has worked with prestigious organizations, including the National Institutes of Health, a component of the US Department of Health & Human Services. His work has significantly impacted the field of cancer treatment and drug delivery systems.
Collaborations
Jerry has collaborated with notable individuals in his field, including Raymond W Klecker, Jr and Lawrence W Anderson. These collaborations have contributed to the advancement of his research and innovations.
Conclusion
Jerry M Collins is a pioneering inventor whose work in antitumor therapy has the potential to change the landscape of cancer treatment. His innovative approaches and collaborations continue to drive advancements in this critical area of healthcare.